



GENSIGHT BIOLOGICS
A French Société Anonyme (corporation)
with share capital of 3,286,662.38 Euros
74 rue du Faubourg Saint Antoine
75012 Paris
751 164 757 - Paris Trade and Companies Registry

RENEWAL OF THE BOARD DIRECTOR'S MANDATE, GENERAL MEETING OF
May 13, 2025

USUAL NAME: Elsy Boglioli

PERSONAL HOME ADDRESS: 35 rue de Bellechasse 75007 Paris, France

DATE AND PLACE OF BIRTH: 2 February 1982 in Paris, France

BIOGRAPHY:

Elsy Boglioli is the founder and CEO of *Bio-Up*, a healthcare advisory firm supporting companies in strong scale up or transformation phases, mainly in the field of cell and gene therapy. She has far-reaching expertise and a broad network within the pharma and medtech industries.

Before she created *Bio-Up*, Elsy was Executive Vice President, Chief Operating Officer at *Cellectis*, a French biotechnology company focused on gene editing and its applications in oncology. At *Cellectis* she led various strategic and operational functions: strategy, business development, clinical trials program management, as well as manufacturing, with the objective of building in-house capacity. Prior to joining *Cellectis*, Elsy worked at the *Boston Consulting Group (BCG)* for 12 years. She served as Partner and Managing Director in the Paris Office, was the leader of *BCG's* biotech-focused business in Europe. She worked closely with Biotech and Pharma companies on topics such as specialty product launch optimization, partnering and M&A.

Elsy graduated from the *Ecole Polytechnique* in Paris, France and holds a master's degree in economy and management from the *Pompeu Fabra University* in Barcelona, Spain. She also completed a College degree in Immuno-oncology at *Institut Gustave Roussy*.

OFFICES IN THE COMPANY: Independent director since 2020, Chairman of the Nomination Committee.

NUMBER OF SHARES OF THE CORPORATION OWNED: 0



GENSIGHT BIOLOGICS
A French Société Anonyme (corporation)
with share capital of 3,286,662.38 Euros
74 rue du Faubourg Saint Antoine
75012 Paris
751 164 757 - Paris Trade and Companies Registry

RENEWAL OF THE BOARD DIRECTOR'S MANDATE, GENERAL MEETING OF
May 13, 2025

USUAL NAME: Simone Seiter

PERSONAL HOME ADDRESS: Schillerstr. 29 61350 Bad Homburg, Germany

DATE AND PLACE OF BIRTH: 22 December 1966 – Offenburg Germany

BIOGRAPHY:

Simone Seiter, M.D., Ph.D has served as a director since April 2017. Dr. Seiter has worked as Senior Partner with *Simon-Kucher & Partners* since 2020 leading the global Life Sciences commercial strategy consulting practice. In 2020 she co-founded *Priothera* a oncology focused pre-commercial biotech company based in Ireland where she now serves as the head of the clinical and commercial advisory board. She is also an independent director of *Mediphage Bioceuticals Inc* (Toronto, Canada) since 2023. Prior to joining *Simon-Kucher & Partners* she worked as a Vice President with *IQVIA* (formerly *QuintilesIMS*) based in Frankfurt, Germany from 2006 to 2019. Prior to joining *IQVIA* she worked at *Capgemini* as a consultant for six years and served as a postdoctoral Fellow at the *National Institutes of Health* (United States) for two years. Previously, Dr. Seiter worked at the *Universities of Heidelberg and Homburg, Germany* as board certified dermatologist.

Dr. Seiter holds an M.D. Ph.D. degree from the *University of Heidelberg* and an MBA from the *University of Applied Sciences in Neu-Ulm, Germany*..

OFFICES IN THE COMPANY: Independent director since 2019, Member of the Audit and Compensation Committee.

NUMBER OF SHARES OF THE CORPORATION OWNED: 0



GENSIGHT BIOLOGICS
A French Société Anonyme (corporation)
with share capital of 3,286,662.38 Euros
74 rue du Faubourg Saint Antoine
75012 Paris
751 164 757 - Paris Trade and Companies Registry

RENEWAL OF THE BOARD DIRECTOR'S MANDATE, GENERAL MEETING OF
May 13, 2025

USUAL NAME: Maritza McIntyre

PERSONAL HOME ADDRESS: 972 Ann St. Birmingham, MI 48009, USA

DATE AND PLACE OF BIRTH: 14 May 1965 - Detroit, Michigan USA

BIOGRAPHY:

Maritza C. McIntyre, Ph.D. is the President of *Advanced Therapies Partners, LLC*. Dr. McIntyre has over 25 years of experience in the development, evaluation and regulation of biological and small molecule products within startup biotech firms, the *Food and Drug Administration (FDA)*, and as a consultant. Dr. McIntyre was a product reviewer and ultimately Branch Chief in the Division of Cellular and Gene Therapies at *FDA/CBER*, where she was actively involved in policy development and liaison activities to stakeholder groups. She has since worked in regulatory affairs and product development at Bavarian Nordic, *REGENXBIO, Inc.* and *NanoCor Therapeutics* (acquired by *Bayer*). She served as Executive Vice President of Regulatory Affairs and Product Development at *Bamboo Therapeutics* where, as part of the senior management team, she participated in portfolio selection, product development and fundraising that resulted in an initial \$50 million finance round and ultimate the sale of the company to *Pfizer*. Most recently she served as the Chief Development Officer at *StrideBio, Inc.* where she oversaw the development of neurological gene therapy programs partnered with *Takeda* and *Sarepta* as well as internal cardiac gene therapy programs.

As president of *Advanced Therapies Partners LLC*, Dr. McIntyre provides strategic regulatory and product development advice to biotech companies, academics, and venture capital firms.

Through her participation in industry associations, including *ASGCT* and the *Standards Coordinating Body* she has continued to contribute to gene therapy regulatory policy development.

Dr. McIntyre received a Ph.D. in virology from the *University of Chicago* and graduated magna cum laude with an Honors B.S. in biology from *Wayne State University*.

OFFICES IN THE COMPANY: Independent director since 2019, Member of the Nomination Committee.



NUMBER OF SHARES OF THE CORPORATION OWNED: 0



GENSIGHT BIOLOGICS
A French Société Anonyme (corporation)
with share capital of 3,286,662.38 Euros
74 rue du Faubourg Saint Antoine
75012 Paris
751 164 757 - Paris Trade and Companies Registry

RENEWAL OF THE BOARD DIRECTOR'S MANDATE, GENERAL MEETING OF
May 13, 2025

LEGAL CORPORATE NAME: Sofinnova Partners SAS

REGISTERED OFFICE: 7/11 Boulevard Haussman – 75009 Paris, FRANCE

RCS: 413 388 596

REGISTRATION DATE: 25 August 1997

COMPANY PURPOSE: Sofinnova Partners is an independent venture capital firm, a European leader in funding for start-ups, early-stage companies, corporate spin-offs and occasionally turnaround situations

OFFICES IN THE COMPANY: None

NUMBER OF SHARES OF THE CORPORATION OWNED: 29,913,274

INFORMATION REGARDING THE EXPECTED PERMANENT REPRESENTATIVE

USUAL NAME: Cédric Moreau

PERSONAL HOME ADDRESS: Sofinnova Partners - 7/11 Boulevard Haussman – 75009 Paris, FRANCE

DATE AND PLACE OF BIRTH: 15 July 1976 – Clamart, FRANCE

BIOGRAPHY:

Cedric Moreau has served as the representative of *Sofinnova Partners* since June 2019. Cédric joined *Sofinnova Partners* in June 2018 and brought 18 years of experience in life sciences investment banking. He brings to the *Sofinnova Crossover* team his transactional expertise in the biopharma industry, with an extensive network of Key Opinion Leaders (KOLs), bankers and lawyers.

Cedric joined from *Oddo BHF* where he was Managing Director and Head of Healthcare at the Corporate Finance department. In 2017, *Oddo BHF* was top ranked in the European biotech equity capital market deals league tables. Prior to this, he was Director at *Bryan Garnier & Co* where he completed several sizeable cross border transactions. In total, he has managed transactions (IPO/ FOn/ PIPEs) in European healthcare companies totaling around €2bn in value. He is well known to the *Sofinnova* team having executed several mandates for portfolio companies. Before his corporate finance career, he spent 10 years as a Healthcare Equity



Analyst and was several times EXTEL top ranked (awarded for both individual and team performances) at *Natixis* and *Fortis*. He was in charge of both listed biotech and pharma companies coverage. He brings to the Crossover team his transactional expertise in the biopharma industry, with an extensive network of Key Opinion Leaders (KOLs), bankers and lawyers.

Cedric holds a Master's in Economics and post-graduate diploma in Finance and Taxation (*Sorbonne*) and Diploma from the *Société Française des Analystes Financiers (SFAF)*.

OFFICES IN THE COMPANY: Director since 2019, Member of the Audit and Compensation Committee.

NUMBER OF SHARES OF THE CORPORATION OWNED: 0



GENSIGHT BIOLOGICS
A French Société Anonyme (corporation)
with share capital of 3,286,662.38 Euros
74 rue du Faubourg Saint Antoine
75012 Paris
751 164 757 - Paris Trade and Companies Registry

NOMINEES TO THE BOARD OF DIRECTORS, GENERAL MEETING OF MAY 13, 2025

USUAL NAME: José-Alain Sahel

PERSONAL HOME ADDRESS: 2452 MOUNT ROYAL ROAD, Pittsburgh, PA 15217, USA

DATE AND PLACE OF BIRTH: 12 July 1955 at Tlemcen, Algeria

BIOGRAPHY:

José-Alain Sahel, MD, is an internationally renowned French ophthalmologist and scientist, born in 1955 in Tlemcen (Algeria). Graduating from the Faculty of Medicine in Paris (medalist in 1980), he specialized in ophthalmology in Strasbourg, Paris and Harvard University, and then pursued an exceptional academic and hospital career in France, the United Kingdom, and the United States.

Professor of Ophthalmology at the Louis Pasteur University of Strasbourg since 1988, he subsequently led the ophthalmology department at the National Eye Hospital of Quinze-Vingts in Paris from 2001, and founded the Vision Institute in 2008, which has become one of the largest integrated research centers in Europe for vision diseases. He was a Professor at Sorbonne Université and also held the Cumberlege Chair of Biomedical Sciences at the Institute of Ophthalmology at University College London. He is currently Distinguished Professor and Chair of the Department of Ophthalmology at the University of Pittsburgh, where he directs the UPMC Vision Institute.

A pioneer in understanding and treating incurable retinal diseases, his work has led to major advances in gene therapy, optogenetics, artificial retina, and neuroprotection, all leading to first-in-human trials. He is notably the co-discoverer of the cone viability factor (RdCVF), paving the way for new therapeutic strategies to preserve central vision in retinitis pigmentosa and age-related macular degeneration.

Author of more than 700 scientific publications and inventor of numerous patents, José-Alain Sahel has received prestigious distinctions, including the Legion of Honor, the National Order of Merit, the CNRS Innovation Medal, and the Wolf Prize in Medicine 2024, which recognizes his exceptional contributions to vision restoration, particularly through optogenetics. He is a member of several academies, including the Académie des Sciences-Institut de France, the Académie Nationale de Chirurgie, the Académie des Technologies, the German National Academy of Sciences Leopoldina and is a Fellow of the National Academy of Inventors, USA.

OFFICES IN THE COMPANY: Censor of the Board of Directors for more than 12 years.



NUMBER OF SHARES OF THE CORPORATION OWNED: 0